<DOC>
	<DOCNO>NCT00346216</DOCNO>
	<brief_summary>To answer question overall benefit : risk celecoxib compare two commonly prescribe traditional ( non-selective ) nonsteroidal anti-inflammatory drug ( NSAIDs ) treatment arthritis pain . For purpose , patient osteoarthritis rheumatoid arthritis risk develop cardiovascular disease recruit . The cardiovascular , gastrointestinal renal safety symptomatic benefit treatment group assess accordingly .</brief_summary>
	<brief_title>Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Subjects osteoarthritis rheumatoid Arthritis risk develop cardiovascular disease require eligible chronic , daily therapy NSAID control arthritis sign symptom . Subjects recent cardiovascular event , unstable cardiovascular condition , major surgery ( cardiac noncardiac ) within 3 month prior randomization ; Subjects medical laboratory abnormality would make subject inappropriate entry trial Subjects require treatment aspirin &gt; 325 mg /day Subjects know hypersensitivity celecoxib , ibuprofen , naproxen , aspirin esomeprazole , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>